|

Mechanisms for Activation of Beige Adipose Tissue in Humans

RECRUITINGPhase 2Sponsored by Philip Kern
Actively Recruiting
PhasePhase 2
SponsorPhilip Kern
Started2020-12-07
Est. completion2026-06-25
Eligibility
Age35 Years – 65 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT04666636

Summary

Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance and adipose tissue in prediabetic patients

Eligibility

Age: 35 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria:

* BMI 27-45
* prediabetes (A1c 5.7-6.4)
* impaired fasting glucose or impaired glucose tolerance

Exclusion Criteria:

* diabetes
* chronic use of anti-diabetic medication
* acute or chronic inflammatory condition
* unstable medical condition
* cancer
* renal insufficiency
* any contraindication for Mirabegron
* BMI \>45

Conditions2

DiabetesPreDiabetes

Locations1 site

University of Kentucky
Lexington, Kentucky, 40536
Zach Leicht859-218-1397zachary.leicht@uky.edu

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.